✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Antineoplaston A10 is an investigational drug.
There have been 55 clinical trials for Antineoplaston A10. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Central Nervous System Neoplasms, Nervous System Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Burzynski Research Institute and [disabled in preview].
There are two hundred and forty US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Antineoplaston A10
|Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma||Burzynski Research Institute||Phase 3|
|Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma||Burzynski Research Institute||Phase 3|
|Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia||Burzynski Research Institute||Phase 2|
Top disease conditions for Antineoplaston A10
Top clinical trial sponsors for Antineoplaston A10
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Antineoplaston A10||See Plans and Pricing||Synergistic compositions for treating microbial infections||University of Rochester (Rochester, NY) Temple University--Of the Commonwealth System of Higher Education (Philadelphia, PA)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Combination methods for treating cancers||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Phosphatidylinositol 3-kinase inhibitors||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Crystalline forms of tyrosine kinase inhibitors and their salts||Purdue Pharma, L.P. (Stamford, CT)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders||CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Antineoplaston A10||See Plans and Pricing||Multi-component nanochains||Case Western Reserve University (Cleveland, OH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Antineoplaston A10||Australia||AU2015339039||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||Canada||CA2965839||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||China||CN107106533||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||European Patent Office||EP3212183||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||Japan||JP2017538675||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||Japan||JP6590924||2034-10-31||See Plans and Pricing|
|Antineoplaston A10||World Intellectual Property Organization (WIPO)||WO2016070021||2034-10-31||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|